In a significant shake-up at the U.S. Food and Drug Administration (FDA), Commissioner Marty Makary has resigned amid escalating pressure from pharmaceutical leaders, the vaping industry, and anti-abortion advocates. His departure is widely viewed as symptomatic of ongoing chaos within public health policy under the Trump administration. Acting FDA leader Kyle Diamantas has taken over, promising to implement a pro-life agenda while navigating a leadership void that raises concerns about drug approvals and innovation. Analysts speculate on the implications of Makary’s tumultuous tenure, particularly regarding fruit-flavored vapes and other regulatory shifts in the agency. Stakeholders are expressing hope for a new commissioner who can stabilize relations between the FDA and its critics, as the agency seeks to regain its footing amidst growing uncertainty.